PedAM
Pediatric Disease Annotations & Medicines
| Disease | hepatitis |
| Symptom | C0151317|chronic infection |
| Sentences | 332 |
| PubMedID- 21994626 | Decreased pdc function has been observed in a number of human persistent virus infections, including chronic infection with hepatitis b or c viruses (hbv or hcv) or human t cell leukemia virus type i (htlv-i) . |
| PubMedID- 24397793 | chronic infection with hepatitis b virus (hbv) is a major cause of death from cirrhosis and liver cancer, chiefly in south-east asia and sub-saharan africa . |
| PubMedID- 21168955 | It is thought that 80% of hepatocellular carcinomas are linked to chronic infections with the hepatitis b (hbv) or hepatitis c (hcv) viruses. |
| PubMedID- 25646075 | chronic infection with hepatitis b virus (hbv) is the major cause of hcc. |
| PubMedID- 25884472 | Most cases of hcc are attributed to chronic infection with either hepatitis b or c virus 2. |
| PubMedID- 23509784 | chronic infection with hepatitis b virus (hbv) is associated with the majority of cases of liver cirrhosis (lc) in china. |
| PubMedID- 26573807 | The main risk factors for hcc are chronic infections with either hepatitis b virus (hbv) or hepatitis c virus (hcv), making up approximately 75–85 % of all cases, as well as excessive alcohol consumption, which is responsible for about 40 % of hcc development in western countries . |
| PubMedID- 21316532 | Background: cirrhosis developing during chronic infection with the hepatitis c virus (hcv) poses a risk of anticipated liver-related death, therefore representing a dominant indication to anti-hcv therapy. |
| PubMedID- 22276183 | chronic infection with hepatitis b virus (hbv) is a major worldwide issue in public health and is one of the best known high-risk factors for cirrhosis and hepatocellular carcinoma (hcc) . |
| PubMedID- 24621321 | chronic infection with hepatitis c virus (hcv) affects up to 170 million individuals worldwide 1 and may lead to progressive hepatic fibrosis and cirrhosis, with risk of liver failure and hepatocellular carcinoma. |
| PubMedID- 21365069 | chronic infection with the hepatitis b and/or c virus causes significant morbidity and mortality. |
| PubMedID- 19773667 | Objectives: although chronic infection with the hepatitis c virus (hcv) may lead to the development of cirrhosis and its complications, little data are available on progression to the decompensated stage in a hetereogeneous population. |
| PubMedID- 23304062 | chronic infection with hepatitis b virus (hbv) affects more than 350 million people worldwide and continues to be an important cause of morbidity and mortality 1. |
| PubMedID- 24240052 | Odds ratios (or) for hcc were obtained through multiple logistic regression models, controlling for potentially confounding factors, including chronic infection with hepatitis b/c viruses. |
| PubMedID- 23437062 | chronic infection with hepatitis b virus (hbv) and hepatitis c virus (hcv), alcohol abuse, environmental and occupational toxins, as well as certain metabolic and immune disorders are risk factors of hcc . |
| PubMedID- 20106936 | An example is chronic infection with hepatitis c virus, where the initial infection may be asymptomatic for decades. |
| PubMedID- 23483081 | Background: epidemiological evidence has clearly indicated that chronic infection with the hepatitis b virus (hbv) is the major risk factor for developing hepatocellular carcinoma (hcc). |
| PubMedID- 24779356 | chronic infection with hepatitis b virus (hbv) results in an estimated 786 000 deaths annually worldwide 1. infected individuals may remain asymptomatic for long periods but are at risk of progressive liver disease, and can transmit the virus to other susceptible individuals. |
| PubMedID- 24316982 | The most common risk factor for developing hepatocellular carcinoma (hcc) is chronic infection with hepatitis b virus (hbv). |
| PubMedID- 24717818 | An estimated 3.2 million persons in the united states have chronic infection with hepatitis c virus (hcv). |
| PubMedID- 22753481 | chronic infection with hepatitis b virus (hbv) is a major risk factor for the development of hepatocellular carcinoma (hcc). |
| PubMedID- 24596581 | chronic infection with hepatitis e virus has been reported in immunocompromised patients, including several patients with leukemia. |
| PubMedID- 22966221 | chronic infection with the hepatitis c virus (hcv) is a major risk factor for the development of hepatocellular carcinoma (hcc). |
| PubMedID- 23575038 | chronic infection with hepatitis c virus (hcv) affects >170 million individuals, approximately 3% of the world population, and is responsible for approximately 350,000 deaths every year 1. |
| PubMedID- 22184515 | The main hepatic complications of multiple transfusions include acute and chronic infection with hepatitis b and c and iron overload. |
| PubMedID- 21143343 | chronic infection with the hepatitis b virus (hbv) is a major risk factor for development of end-stage liver disease, including cirrhosis, liver failure and primary liver cancer. |
| PubMedID- 21682827 | Although chronic infection with hepatitis b virus (hbv) and/or hepatitis c virus (hcv) are the most important risk factors for the development of hepatocellular carcinoma (hcc) worldwide, the proportion of hcc patients negative for the hepatitis b surface antigen and hepatitis c antibody, so-called "non-b non-c hcc", is rapidly increasing, especially in japan. |
| PubMedID- 20429960 | chronic infection with hepatitis b virus (hbv) occurs in approximately 6% of the world's population and carriers of the virus are at risk for hepatocellular carcinoma and cirrhosis. |
| PubMedID- 20107090 | chronic infection with hepatitis b virus (hbv) is an important cause of cirrhosis and cancer of the liver. |
| PubMedID- 23805355 | chronic infections with hepatitis b viruses or hepatitis c viruses have both been recognized as human liver carcinogens with a combined attributable fraction of at least 75% of all hcc cases. |
| PubMedID- 24984340 | Recently approved direct-acting antiviral agents (daa) for the treatment of chronic infection with hepatitis c virus (hcv) genotype 1, protease inhibitors (pi) boceprevir and telaprevir, have substantially increased the rates of sustained virologic response in the treatment of naive and experienced patients. |
| PubMedID- 22878466 | Mental health problems frequently occur in chronic infection with the hepatitis c virus (hcv) and during antiviral treatment with pegylated interferon-alpha (pegifnalpha) and ribavirin. |
| PubMedID- 23118525 | chronic infection with the hepatitis c virus (hcv) is a major cause of liver-related invalidity and mortality worldwide. |
| PubMedID- 25579804 | Continuous hepatic inflammation as a result of chronic infection with the hepatitis c virus may lead to the development of fibrosis and eventually cirrhosis. |
| PubMedID- 25646622 | chronic infection with hepatitis b virus (hbv) affects over 300 million individuals worldwide . |
| PubMedID- 20173735 | chronic infection with the hepatitis c virus (hcv) affects 170 million people worldwide and is an important cause of liver-related morbidity and mortality. |
| PubMedID- 23301066 | The underlying fibrosis is often driven by chronic infection with hepatitis b virus (hbv). |
| PubMedID- 23963804 | In endemic areas of sub-saharan africa and asia, plc largely arises from chronic infection with hepatitis b virus (hbv) and ingestion of aflatoxins. |
| PubMedID- 23202511 | Epidemiological studies indicate that chronic infection with hepatitis b virus (hbv) is the leading cause for the development of hepatocellular carcinoma (hcc) 1. |
| PubMedID- 21195370 | Sixty percent of all hccs in asia and africa are related to chronic infection with the hepatitis b virus (hbv) compared to only 20% of hcc cases in europe, japan and usa. |
| PubMedID- 26434859 | chronic infection with the hepatitis b virus is the major factor leading to hcc progression since it causes the liver injury. |
| PubMedID- 23788462 | chronic infection with hepatitis b virus (hbv) can result in progressive liver disease, hepatocellular carcinoma (hcc), and death in as many as 25% of hepatitis b surface antigen (hbsag) carriers.1 in patients with end-stage liver disease, liver transplantation (lt) is often the only treatment option. |
| PubMedID- 22869395 | Background and aim: hepatocellular carcinoma (hcc) is the most frequent form of primary liver cancer and chronic infection with hepatitis c virus is one of the main risk factors for hcc. |
| PubMedID- 25081062 | Background: chronic infection with hepatitis c virus (hcv) is a risk factor for liver diseases such as fibrosis, cirrhosis and hepatocellular carcinoma. |
| PubMedID- 22312395 | chronic infection with hepatitis b virus (hbv) is a major global health problem, affecting more than 400 million people worldwide. |
| PubMedID- 23852676 | chronic infection with hepatitis b virus (hbv) is a global health problem. |
| PubMedID- 23185284 | The etiologic importance of chronic infection with hepatitis b virus (hbv) and hepatitis c virus (hcv) in hcc has been well established . |
| PubMedID- 24708820 | Morocco is a country of intermediate endemicity for chronic infections with hepatitis b (hbv) and c (hcv) viruses, where a consistently low level of food contamination by aflatoxins b1. |
| PubMedID- 24175062 | chronic infection with hepatitis c virus (hcv) is treated with a combined therapy of peginterferon-α-2a (pegifn-α-2a) or pegifn-α-2b and ribavirin. |
| PubMedID- 20163377 | Background: chronic infection with hepatitis c, genotype 2/3, responds better than other genotypes to peginterferon and ribavirin treatment. |